antihmgb1 antibody (Servicebio Inc)
90
Structured Review
Servicebio Inc
antihmgb1 antibody
Antihmgb1 Antibody, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antihmgb1+antibody/ngal+gb111134+antibody/pm39556940-135-69-72
Average 90 stars, based on 1 article reviews
Antihmgb1 Antibody, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/antihmgb1+antibody/ngal+gb111134+antibody/pm39556940-135-69-72
Average 90 stars, based on 1 article reviews
antihmgb1 antibody - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Incubation:Article Title: Overcoming tumor hypoxic bismuth-based ternary heterojunctions enable defect modulation-augmented tumor sonocatalytic immunotherapy. Article Snippet: Inducing reactive oxygen species (ROS) via sonocatalysis to initiate inflammatory programmed cell death (PANoptosis) and immunogenic cell death (ICD) presents a promising strategy for activatable cancer immunotherapy.. However, the limited ROS generation by sonosensitizers under ultrasound and the immunosuppressive tumor microenvironment hinder the efficiency of sono-immunotherapy.. To overcome these challenges, a bismuth-based ternary heterojunction, Bi@Bi2O3–Pt-PEG (BBOP), was developed for sonocatalytic therapy aimed at activating immune responses. Staining:Article Title: Overcoming tumor hypoxic bismuth-based ternary heterojunctions enable defect modulation-augmented tumor sonocatalytic immunotherapy. Article Snippet: Inducing reactive oxygen species (ROS) via sonocatalysis to initiate inflammatory programmed cell death (PANoptosis) and immunogenic cell death (ICD) presents a promising strategy for activatable cancer immunotherapy.. However, the limited ROS generation by sonosensitizers under ultrasound and the immunosuppressive tumor microenvironment hinder the efficiency of sono-immunotherapy.. To overcome these challenges, a bismuth-based ternary heterojunction, Bi@Bi2O3–Pt-PEG (BBOP), was developed for sonocatalytic therapy aimed at activating immune responses. Fluorescence:Article Title: Overcoming tumor hypoxic bismuth-based ternary heterojunctions enable defect modulation-augmented tumor sonocatalytic immunotherapy. Article Snippet: Inducing reactive oxygen species (ROS) via sonocatalysis to initiate inflammatory programmed cell death (PANoptosis) and immunogenic cell death (ICD) presents a promising strategy for activatable cancer immunotherapy.. However, the limited ROS generation by sonosensitizers under ultrasound and the immunosuppressive tumor microenvironment hinder the efficiency of sono-immunotherapy.. To overcome these challenges, a bismuth-based ternary heterojunction, Bi@Bi2O3–Pt-PEG (BBOP), was developed for sonocatalytic therapy aimed at activating immune responses. Microscopy:Article Title: Overcoming tumor hypoxic bismuth-based ternary heterojunctions enable defect modulation-augmented tumor sonocatalytic immunotherapy. Article Snippet: Inducing reactive oxygen species (ROS) via sonocatalysis to initiate inflammatory programmed cell death (PANoptosis) and immunogenic cell death (ICD) presents a promising strategy for activatable cancer immunotherapy.. However, the limited ROS generation by sonosensitizers under ultrasound and the immunosuppressive tumor microenvironment hinder the efficiency of sono-immunotherapy.. To overcome these challenges, a bismuth-based ternary heterojunction, Bi@Bi2O3–Pt-PEG (BBOP), was developed for sonocatalytic therapy aimed at activating immune responses. |